This is supported by the facts that—(i) The AhR is emerging and suitable therapeutic target in IBD; (ii) Avitriptan is a ligand and agonist of the AhR; (iii) Avitriptan passed phase I and phase II of clinical studies, which may accelerate its introduction in clinical use; (iv) Orally Avitriptan has low bioavailability and it is not toxic to intestinal cells, which favors its local use in IBD treatment without having undesirable systemic effects. Here, AHR is linked to inflammatory bowel disease.